Opinion|Videos|May 19, 2025
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Author(s)Neal Shore, MD, FACS
Research highlights the significant benefits of achieving ultra-low PSA levels in metastatic hormone-sensitive prostate cancer, delaying disease progression effectively.
Advertisement
Episodes in this series
Rationale for Ultra-Low PSA Threshold Analysis
Key Themes:
- Post hoc analysis focusing on PSA response thresholds
- Particular focus on ultra-low PSA threshold (<0.02 ng/mL)
- PSA as a surrogate biomarker in advanced prostate cancer
Expert Insights:
- Dr Shore explained the rationale for examining the ultra-low PSA threshold of <0.02 ng/mL in the ARANOTE trial.
The discussion highlighted the historical relevance of low PSA levels in predicting treatment outcomes and the potential increased sensitivity of this threshold.
Advertisement
Related to this article
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Biomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Advertisement
Advertisement
Trending on Urology Times
1
PTEN loss: From biomarker to treatment strategy in mHSPC
2
Q&A: Gary Kirsh, MD, on health policy for independent urology
3
Modern BCG outperforms historic benchmarks in high-risk NMIBC
4
Q&A: Suzanne B. Merrill, MD, FACS, on treating high-risk NMIBC
5